Skip to content
Screener

Insulet PODD Q3 2025 earnings

Reported November 6, 2025 · Before market open

Revenue$706.3MBeat by $27.9M
EPS$1.24Beat by $0.10
Revenue estimate$678.4M
EPS estimate$1.14

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$833.3M
EPS estimate$1.59

Financials

Q3 2025

Income statement

See full
Revenue$706.3M+29.9%
Gross profit$510.1M+35.3%
Operating income$117.7M+33.6%
Net income$87.6M+13.0%
EPS (diluted)$1.24+14.8%

Balance sheet

See full
Cash & equivalents$757.4M-16.1%
Total debt$1.1B-25.9%
Total equity$1.4B+23.8%
Total assets$3.0B+0.1%

Cash flow

See full
Operating cash flow$125.7M+16.1%
CapEx$25.6M-4.1%
Free cash flow$100.1M+22.7%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$21.73B+33.3%
Enterprise value$22.07B+30.7%
P/E88.3×+49.5×
P/S8.6×+0.4×

Profitability

See full
Gross margin71.5%+2.1pp
Operating margin17.3%+1.9pp
Net margin9.8%-11.5pp
FCF margin16.8%+5.3pp

Returns & leverage

See full
Return on equity19.7%-29.1pp
Debt / equity0.8×-0.5×
Current ratio2.9×-0.8×

Segments

By product

See full
International$202.1M+46.6%
Drug Delivery$7.1M-31.1%

FAQ

When did Insulet report Q3 2025 earnings?
Insulet (PODD) reported Q3 2025 earnings on November 6, 2025 before market open.
What were Insulet's Q3 2025 revenue and EPS?
Insulet reported revenue of $706.3M and eps of $1.24 for Q3 2025.
Did Insulet beat estimates in Q3 2025?
Revenue beat the consensus estimate of $678.4M by $27.9M. EPS beat the consensus estimate of $1.14 by $0.10.
How did Insulet's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 89.6% from $372.6M a year earlier and eps grew 37.8% from $0.90.
Where can I find Insulet's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001145197-25-000067) and the 10-Q periodic report (0001145197-25-000069) directly on SEC EDGAR. The filing index links above go to sec.gov.